John Latham
Consulente / Consigliere presso Accelerator Services Corp
Profilo
John A.
Latham was the founder of Lundbeck Seattle BioPharmaceuticals, Inc. founded in 2004, where he held the title of Chief Scientific Officer from 2012 to 2019.
He also held founding positions at Darwin Molecular Corp as Founding Director from 1994 to 1998, and at Gilead Sciences, Inc. as Principal from 1989 to 1994.
He was also VP-Gene Function & Target Validation at Celltech Group Plc from 1998 to 2004.
Currently, Dr. Latham serves as an Advisory Board member at Accelerator Services Corp.
Dr. Latham holds a doctorate degree from Massachusetts Institute of Technology and an undergraduate degree from Colorado State University.
Posizioni attive di John Latham
| Società | Posizione | Inizio |
|---|---|---|
Accelerator Services Corp
 Accelerator Services Corp Investment ManagersFinance Accelerator Services Corp (Accelerator Services) is a venture capital firm founded in 2003 by Carl Weissman and Rodney F. Burgar. The firm is headquartered in Seattle, Washington. | Consulente / Consigliere | - |
Precedenti posizioni note di John Latham
| Società | Posizione | Fine |
|---|---|---|
| ALDER BIOPHARMACEUTICALS, INC. | Fondatore | 05/04/2019 |
Celltech Group Plc
 Celltech Group Plc BiotechnologyHealth Technology Celltech Group Plc was one of the leading European biotechnology company which is engaged in discovery and development of innovative drugs. The company was located in Slough, United Kingdom. | Corporate Officer/Principal | 01/01/2004 |
Darwin Molecular Corp
 Darwin Molecular Corp Miscellaneous Commercial ServicesCommercial Services Part of UCB SA, Darwin Molecular Corp is a biotechnology research and development firm. The company is based in Bothell, WA. Darwin Molecular was acquired by Celltech Group Plc on November 20, 1996 for $120 million. | Corporate Officer/Principal | 01/01/1998 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/01/1994 |
Formazione di John Latham
| Massachusetts Institute of Technology | Doctorate Degree |
| Colorado State University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| Aziende private | 4 |
|---|---|
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
Celltech Group Plc
Celltech Group Plc BiotechnologyHealth Technology Celltech Group Plc was one of the leading European biotechnology company which is engaged in discovery and development of innovative drugs. The company was located in Slough, United Kingdom. | Health Technology |
Darwin Molecular Corp
Darwin Molecular Corp Miscellaneous Commercial ServicesCommercial Services Part of UCB SA, Darwin Molecular Corp is a biotechnology research and development firm. The company is based in Bothell, WA. Darwin Molecular was acquired by Celltech Group Plc on November 20, 1996 for $120 million. | Commercial Services |
Accelerator Services Corp
Accelerator Services Corp Investment ManagersFinance Accelerator Services Corp (Accelerator Services) is a venture capital firm founded in 2003 by Carl Weissman and Rodney F. Burgar. The firm is headquartered in Seattle, Washington. | Finance |
- Borsa valori
- Insiders
- John Latham
